Reid Hoffman, a pivotal figure in the tech industry and co-founder of LinkedIn, is stepping down from Microsoft’s board of directors after a decade of service. The announcement comes as Hoffman prepares to dedicate more time to his latest venture, Manus, an artificial intelligence startup focused on drug discovery.

Hoffman’s tenure on Microsoft’s board began in 2016, following the tech giant’s landmark $26.2 billion acquisition of LinkedIn. During his time with Microsoft, he also witnessed and participated in significant investments, including the company’s initial $1 billion stake in OpenAI in 2019. Hoffman was an early investor in OpenAI and served on its board until 2023, eventually stepping down due to potential conflicts of interest. He was also a board member when Microsoft engaged in a substantial $650 million deal with Inflection AI, Hoffman’s AI startup, which involved acquiring talent rather than the company outright, including Inflection co-founder Mustafa Suleyman.

Now, Hoffman is shifting his focus to “founder mode” with Manus, a company he co-founded. Manus has already secured over $50 million in seed funding and is reportedly developing “Move 37” AI, a technology aimed at advancing AI’s capabilities in chemistry to combat diseases like cancer. While Hoffman holds the title of chairman, the CEO role at Manus is filled by Dr. Siddhartha Mukherjee, a renowned physician, biologist, and author. Hoffman expressed his enthusiasm for dedicating more attention to Manus, citing the startup’s significant progress as the driving force behind his decision to leave the Microsoft board.

Key Takeaways

• Reid Hoffman is leaving Microsoft's board after 10 years to focus on his AI startup, Manus.
• Manus is a drug discovery company developing 'Move 37' AI for cancer research.
• Hoffman's departure follows his involvement in Microsoft's investments in OpenAI and its deal with Inflection AI.

Editor’s Analysis & Impact

Reid Hoffman’s strategic move from Microsoft’s board to fully commit to his AI startup, Manus, underscores the accelerating pace of innovation in the AI and biotech sectors. His decision signals a growing trend of prominent tech leaders channeling their expertise and capital into specialized, high-impact ventures. Manus’s focus on ‘Move 37’ AI for drug discovery, particularly in oncology, positions it at the forefront of a critical field where AI promises to revolutionize research and development. This transition could significantly boost Manus’s trajectory, potentially leading to breakthroughs in cancer treatment and further validating the immense potential of AI in healthcare. The move also highlights the increasing convergence of deep tech expertise and venture capital in addressing complex global challenges.

Frequently Asked Questions

Q: What is Reid Hoffman's new focus?
A: Reid Hoffman is stepping down from Microsoft's board to dedicate more time and energy to his AI startup, Manus, which is focused on drug discovery.

Q: What is 'Move 37' AI?
A: 'Move 37' AI refers to artificial intelligence that surpasses human creativity in the field of chemistry, with the goal of developing new treatments, particularly for various cancers.

Q: Who is the CEO of Manus?
A: The CEO of Manus is Dr. Siddhartha Mukherjee, a physician, biologist, and Pulitzer Prize-winning author.